home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

98.82 -5.26 (-5.05%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter ↗

July 27, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Protagonist Therapeutics Reports Granting of Inducement Award

July 18, 2023

Via ACCESSWIRE

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

July 13, 2023

We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning.

Via InvestorPlace

Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive ↗

July 06, 2023

JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35,

Via Benzinga

Expert Ratings for Protagonist Therapeutics ↗

July 06, 2023

Via Benzinga

Where Protagonist Therapeutics Stands With Analysts ↗

June 12, 2023

Via Benzinga

Chart Of The Day: Protagonist Therapeutics - Wide Opinions ↗

June 09, 2023

Via Talk Markets

Protagonist Therapeutics Inc. (NASDAQ: PTGX) is a Stock Spotlight on 6/1

June 01, 2023

Via Investor Brand Network

Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗

July 06, 2023

Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at...

Via Benzinga

Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment ↗

July 05, 2023

Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 04, 2023

Via Benzinga

Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

July 04, 2023

Via ACCESSWIRE

Protagonist Therapeutics: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

4 Analysts Have This to Say About Protagonist Therapeutics ↗

April 27, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 03, 2023

Via Benzinga

Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 03, 2023

Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share.

Via Benzinga

AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday ↗

July 03, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares...

Via Benzinga

US Stocks Mixed; Dow Falls Over 50 Points ↗

July 03, 2023

U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.19% to 34,341.91 while the NASDAQ rose 0.28%...

Via Benzinga

Are (More) Big Gains Ahead for This Small Cap Biotech Stock?

June 28, 2023

With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors.

Via MarketBeat

Topics Initial Public Offering

Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of

June 09, 2023

Via ACCESSWIRE

Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress

June 06, 2023

Via ACCESSWIRE

Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

June 01, 2023

Via ACCESSWIRE

Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment ↗

May 12, 2023

Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of

Via Benzinga

Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm ↗

May 05, 2023

The company is targeting psoriasis with a first-ever mechanism that could rival leaders.

Via Investor's Business Daily

Why Shares of Protagonist Therapeutics Rose This Week ↗

April 20, 2023

The company's lead pipeline candidate is making news.

Via The Motley Fool

Why Protagonist Therapeutics Shares Are Nosediving ↗

April 05, 2023

Protagonist Therapeutics Inc (NASDAQ: PTGX) shares are trading lower by 9.68% to $19.46 Wednesday morning after the company announced pricing of a $100 million public offering of shares of common...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 05, 2023

Via Benzinga

Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock

April 04, 2023

Via ACCESSWIRE

Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

April 04, 2023

Via ACCESSWIRE

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 15, 2023

Via ACCESSWIRE

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com